Evidence and cost, together: how Canadian care is already value-based — and what that means at the point of care.

In Canada, the question of whether a test, drug, or procedure is worth ordering is not just a clinical question. It is also a question about value: does this intervention, given the evidence for its effectiveness, justify its cost within a public system where resources are shared?

This is not a new development. It is built into the design of Canadian guideline bodies. CADTH (Canada's Drug Agency, formerly the Canadian Agency for Drugs and Technologies in Health) and INESSS (Institut national d'excellence en santé et en services sociaux, Québec's health technology assessment body) both explicitly weigh evidence and cost-effectiveness as part of their mandate.

At the point of care, that matters. And it's what Evidens is built to operationalize.

How are Canadian guideline bodies designed differently?

In many healthcare contexts, clinical guidelines and economic analysis run on separate tracks. Guidelines ask: what does the evidence say? Health economics asks: what does the evidence cost the system? In Canada, these are deliberately integrated.

CADTH was established with an explicit mandate to conduct health technology assessments — evaluations that consider not just clinical efficacy and safety, but comparative effectiveness and economic impact. That integration is by design, not by accident.

INESSS performs the same function in Québec: advising the provincial government on the evidence base and cost-effectiveness of drugs, technologies, and clinical practices before they are covered by the provincial formulary or adopted into care pathways.

The result is a guideline apparatus where cost-effectiveness is not an afterthought. It is part of the evidence.

What does CADTH actually do, and why does it matter at the point of care?

CADTH (now formally Canada's Drug Agency) is a pan-Canadian health technology assessment body. It conducts independent reviews of drugs, devices, and clinical practices to advise public drug plans, healthcare ministries, and health systems across Canada.

CADTH's assessments include evaluations of clinical evidence alongside economic models — cost-effectiveness analyses, budget impact analyses, and considerations of appropriate use. These assessments inform what is covered, under what clinical conditions, and at what price point. They represent the national evidence base that Canadian public systems draw on when making coverage and practice decisions.

For the practising clinician, that translates directly: what CADTH has assessed as effective and cost-effective reflects the framework in which Canadian patients access care — not as a constraint on clinical judgment, but as a shared foundation for it.

What is INESSS, and how does it shape care in Québec?

INESSS is Québec's Institut national d'excellence en santé et en services sociaux — the provincial body advising the Gouvernement du Québec on evidence and economic reviews of drugs, technologies, and clinical practices. Its recommendations shape what the RAMQ (Régie de l'assurance maladie du Québec) covers and how Québec's healthcare system adopts new interventions.

For clinicians practising in Québec, INESSS recommendations are directly relevant to what is formulary-listed for their patients, what is covered, and what the evidence base says about appropriate use. INESSS guidance is not peripheral to Québec practice — it defines the system's coverage perimeter.

Is weighing cost the same as rationing care?

No — and the distinction matters for how we think about point-of-care guidance.

Rationing implies withholding clinically beneficial care to reduce expenditure. Stewardship means using evidence to ensure that interventions with strong evidence of benefit reach the patients who benefit from them, and that interventions with weak or absent evidence are not ordered as reflex.

CADTH and INESSS operate on the stewardship principle. Their assessments are designed to identify what works, for whom, at what cost — so that public resources are directed where they produce genuine patient benefit. That is not rationing. It is evidence in the fullest sense of the word: evidence that includes both clinical outcomes and resource implications.

The goal is not cheaper care. It is justified care.

What does value-based care look like at the point of care?

In practice, value-based care at the point of care means the right investigation, ordered because it is guideline-indicated — not reflexively defensive. The right drug, selected because it is evidence-supported and appropriate for this patient in this system. The right referral, to the right specialist, when the clinical indication supports it. And framing every suggestion as something the clinician can defend on the evidence.

How Evidens operationalizes this

Evidens is being built to put the Canadian guideline apparatus — CADTH assessments, INESSS guidance, Choosing Wisely Canada recommendations — at the point of care. Not as a separate reference step that interrupts the clinical workflow, but as part of it.

The goal: when a clinician in Canada asks about a drug, a test, or a treatment approach, the answer reflects what Canadian bodies have assessed — evidence and cost, together. The same integration that CADTH and INESSS have built into the policy layer, operationalized at the clinical encounter.